Alogliptin Benzoate, is an efficacious and selective orally active inhibitor of DPP-4 (dipeptidyl peptidase-4).
Basic Information
English Name: Alogliptin Benzoate
CAS Number: 850649-62-6
Molecular Formula: C25H27N5O4
Molecular Weight: 461.51
Pharmacological Action
Alogliptin Benzoate exerts its pharmacological effects by inhibiting DPP-4 activity, which leads to a reduction in the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This maintenance of hormone levels promotes insulin secretion, thereby contributing to a hypoglycemic effect. Furthermore, GLP-1 has been shown to improve pancreatic β-cell function, further enhancing insulin secretion.
Clinical Applications
Alogliptin Benzoate is primarily researched and used in the treatment of type 2 diabetes mellitus. Clinical studies have demonstrated that alogliptin is well-tolerated in patients with type 2 diabetes, with no dose-limiting toxicity observed. It does not accumulate upon multiple dosing, and dose adjustments are not required for patients with hepatic or renal impairment. Moreover, the pharmacokinetics of alogliptin are unaffected by food intake. Notably, no serious adverse events or deaths were reported in these studies, and no patients withdrew due to adverse reactions.
